Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.

Foti RS, Dalvie DK.

Drug Metab Dispos. 2016 Aug;44(8):1229-45. doi: 10.1124/dmd.116.071753. Epub 2016 Jun 13. Erratum in: Drug Metab Dispos. 2016 Sep;44(9):1516.

PMID:
27298339
2.

Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes.

Eng H, Sharma R, Wolford A, Di L, Ruggeri RB, Buckbinder L, Conn EL, Dalvie DK, Kalgutkar AS.

Drug Metab Dispos. 2016 Aug;44(8):1262-9. doi: 10.1124/dmd.116.070185. Epub 2016 Apr 14.

PMID:
27079250
3.

Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.

Sharma R, Litchfield J, Atkinson K, Eng H, Amin NB, Denney WS, Pettersen JC, Goosen TC, Di L, Lee E, Pfefferkorn JA, Dalvie DK, Kalgutkar AS.

Drug Metab Dispos. 2014 Nov;42(11):1926-39. doi: 10.1124/dmd.114.060087. Epub 2014 Aug 20.

PMID:
25142735
4.

Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.

Smith BJ, Pithavala Y, Bu HZ, Kang P, Hee B, Deese AJ, Pool WF, Klamerus KJ, Wu EY, Dalvie DK.

Drug Metab Dispos. 2014 May;42(5):918-31. doi: 10.1124/dmd.113.056531. Epub 2014 Mar 7.

PMID:
24608633
5.

Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

Silber BM, Rao S, Fife KL, Gallardo-Godoy A, Renslo AR, Dalvie DK, Giles K, Freyman Y, Elepano M, Gever JR, Li Z, Jacobson MP, Huang Y, Benet LZ, Prusiner SB.

Pharm Res. 2013 Apr;30(4):932-50. doi: 10.1007/s11095-012-0912-4. Epub 2013 Feb 16.

6.

The generation, detection, and effects of reactive drug metabolites.

Stachulski AV, Baillie TA, Park BK, Obach RS, Dalvie DK, Williams DP, Srivastava A, Regan SL, Antoine DJ, Goldring CE, Chia AJ, Kitteringham NR, Randle LE, Callan H, Castrejon JL, Farrell J, Naisbitt DJ, Lennard MS.

Med Res Rev. 2013 Sep;33(5):985-1080. doi: 10.1002/med.21273. Epub 2012 Oct 22. Review.

PMID:
23090860
7.

Drug discovery for a new generation of covalent drugs.

Kalgutkar AS, Dalvie DK.

Expert Opin Drug Discov. 2012 Jul;7(7):561-81. doi: 10.1517/17460441.2012.688744. Epub 2012 May 19. Review. Erratum in: Expert Opin Drug Discov. 2012 Sep;7(9):861.

PMID:
22607458
8.

Myeloperoxidase-mediated bioactivation of 5-hydroxythiabendazole: a possible mechanism of thiabendazole toxicity.

Jamieson JD, Smith EB, Dalvie DK, Stevens GJ, Yanochko GM.

Toxicol In Vitro. 2011 Aug;25(5):1061-6. doi: 10.1016/j.tiv.2011.04.007. Epub 2011 Apr 12.

PMID:
21513789
9.

NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.

Zhao SX, Dalvie DK, Kelly JM, Soglia JR, Frederick KS, Smith EB, Obach RS, Kalgutkar AS.

Chem Res Toxicol. 2007 Nov;20(11):1649-57. Epub 2007 Oct 2.

PMID:
17907785
10.
11.

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV Jr, Soliman VF, Schildknegt K.

Drug Metab Dispos. 2007 Jun;35(6):848-58. Epub 2007 Mar 7.

PMID:
17344339
12.
13.

A comprehensive listing of bioactivation pathways of organic functional groups.

Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O'Donnell JP, Boer J, Harriman SP.

Curr Drug Metab. 2005 Jun;6(3):161-225. Review.

PMID:
15975040
15.

Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.

O'Donnell JP, Dalvie DK, Kalgutkar AS, Obach RS.

Drug Metab Dispos. 2003 Nov;31(11):1369-77.

PMID:
14570769
17.

Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.

Harwood HJ Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, Hargrove DM, Martin KA, Tracey WR, Chapman JG, Magee WP, Dalvie DK, Soliman VF, Martin WH, Mularski CJ, Eisenbeis SA.

J Biol Chem. 2003 Sep 26;278(39):37099-111. Epub 2003 Jul 3.

18.

On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.

Kalgutkar AS, Dalvie DK, O'Donnell JP, Taylor TJ, Sahakian DC.

Curr Drug Metab. 2002 Aug;3(4):379-424. Review.

PMID:
12093357
19.

Biotransformation reactions of five-membered aromatic heterocyclic rings.

Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, O'Donnell JP.

Chem Res Toxicol. 2002 Mar;15(3):269-99. Review. No abstract available.

PMID:
11896674
20.

Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors.

Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ.

Chem Res Toxicol. 2001 Sep;14(9):1139-62. Review. No abstract available.

PMID:
11559028
21.
22.

Pharmacokinetics and metabolism of single oral doses of trovafloxacin.

Vincent J, Teng R, Dalvie DK, Friedman HL.

Am J Surg. 1998 Dec;176(6A Suppl):8S-13S.

PMID:
9935250
23.

Characterization of polar urinary metabolites by ionspray tandem mass spectrometry following dansylation.

Dalvie DK, O'Donnell JP.

Rapid Commun Mass Spectrom. 1998;12(8):419-22.

PMID:
9586229
24.

Metabolism of droloxifene in the CD-1 mouse, Fischer-344 rat and cynomolgus monkey.

O'Donnell JP, Khosla NB, Dalvie DK.

Xenobiotica. 1998 Feb;28(2):153-66.

PMID:
9522440
25.

Excretion and metabolism of trovafloxacin in humans.

Dalvie DK, Khosla N, Vincent J.

Drug Metab Dispos. 1997 Apr;25(4):423-7.

PMID:
9107540
26.

Supplemental Content

Loading ...
Support Center